BMS’ and bluebird bio’s Abecma approved by US FDA; first CAR T cell therapy for multiple myeloma Bristol Myers Squibb and bluebird bio, Inc. announced that the US Food and Drug Administration approved Abecma (idecabtagene vicleucel;...
